Skip to main content
. 2021 Jul 31;13(8):1188. doi: 10.3390/pharmaceutics13081188

Figure 5.

Figure 5

(a) XRPD patterns of unprocessed DK-I-60-3, suspension S5 and nanocrystal dispersion F5 with different particle size; (b) diffractograms of nanocrystal dispersion F5 with different particle 3–12° 2 theta; (c) XRPD patterns of nanocrystal dispersions F6 and F8.